Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial-Reference-Cited by-同舟云学术

Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial

Published:2022-04 Issue:4 Volume:33 Page:384-394
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Geyer C.E.,Sikov W.M.,Huober J.,Rugo H.S.,Wolmark N.,O’Shaughnessy J.,Maag D.,Untch M.,Golshan M.,Lorenzo J. Ponce,Metzger O.,Dunbar M.,Symmans W.F.,Rastogi P.,Sohn J.H.,Young R.,Wright G.S.,Harkness C.,McIntyre K.,Yardley D.,Loibl S.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference30 articles.

1. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease;Bianchini;Nat Rev Clin Oncol,2016

2. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO Guideline;Korde;J Clin Oncol,2021

3. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Cardoso;Ann Oncol,2019

4. St. Gallen/Vienna 2021: a brief summary of the consensus discussion on customizing therapies for women with early breast cancer;Thomssen;Breast Care (Basel),2021

5. The survival benefit of neoadjuvant chemotherapy and pCR among patients with advanced stage triple negative breast cancer;Biswas;Oncotarget,2017

Cited by 121 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Can we counterbalance restricted access to innovation through specialized breast cancer care? The REAL-NOTE study;The Breast;2024-12

2. Development and validation of a nomogram for predicting rapid relapse in triple-negative breast cancer patients treated with neoadjuvant chemotherapy;Frontiers in Cell and Developmental Biology;2024-09-02

3. Neoadjuvant Therapy: Current Landscape and Future Horizons for ER-Positive/HER2-Negative and Triple-Negative Early Breast Cancer;Current Treatment Options in Oncology;2024-08-15

4. Clinical Impact of Constitutional Genomic Testing on Current Breast Cancer Care;Clinical Oncology;2024-08

5. Pathologic complete response after neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers;npj Breast Cancer;2024-07-26